Access to the corporate investors' complementary resources: a leverage for innovation in Biotech Venture Capital-Backed companies

Fatima Shuwaikh*, Emmanuelle Dubocage

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

22 Citações (Scopus)

Resumo

Entrepreneurial companies are a vital source of innovation and are financed by investors with different profiles. We examine whether the innovative outputs of entrepreneurial companies are responsive to access to complementary resources from different types of venture capital (VC) funds: “independent venture capital (IVC) and corporate venture capital (CVC)”. We then delve deeper and examine the mechanisms by which we measure if access to investors’ complementary resources has an influence on the innovation performance of the companies they fund. Our sample consists of 1547 U.S. biotechnology companies founded between 1998 and 2013 and financed by IVC or CVC funds. We find that CVC-backed companies display higher rates of innovation output, as measured by their patenting outcomes, than their IVC-backed counterparts. We specify three mechanisms that affect the influence of complementary resources of corporate investors compared to those of IVC: (1) absorptive capacity enhances the ability of the company to grasp and utilize investor knowledge; (2) business similarity helps nurture the technologies of innovative companies, and (3) geographic proximity enables approachability.

Idioma originalEnglish
Número do artigo121374
RevistaTechnological Forecasting and Social Change
Volume175
DOIs
Estado da publicaçãoPublicado - fev. 2022
Publicado externamenteSim

Impressão digital

Mergulhe nos tópicos de investigação de “Access to the corporate investors' complementary resources: a leverage for innovation in Biotech Venture Capital-Backed companies“. Em conjunto formam uma impressão digital única.

Citação